Semaglutide Research Peptide

Semaglutide Research Peptide (GLP1-S)
Lyophilized Format • ≥99% HPLC Purity • Ships in 1–2 Business Days • U.S. Warehouses

Semaglutide (GLP1-S), also designated NN9535, is a synthetic 31 amino acid GLP-1 receptor agonist analog supplied by Nextday Peptides for laboratory and analytical research applications. Structurally modified from native GLP-1 with amino acid substitutions and a C-18 fatty acid chain that enhances albumin binding and stability, Semaglutide is one of the most extensively referenced incretin analogs in current metabolic research. Each vial is independently verified to ≥99% HPLC purity with a Certificate of Analysis available on request. For scientific research use only.

---

Compound Specifications

Compound Name	Semaglutide / GLP1-S / NN9535
Receptor Target	GLP-1 Receptor (GLP-1R)
Amino Acids	31
Molecular Formula	C₁₈₇H₂₉₁N₄₅O₅₉
Molecular Weight	4,113.6 g/mol
Form	Lyophilized powder
Appearance	White to off-white powder
Purity	≥99% (HPLC verified)
Storage	-20°C lyophilized; 2–8°C after reconstitution
CAS Number	910463-68-2
Synonym	NN9535
SKU	NDP-058

---

Mechanism of Action

Semaglutide is a GLP-1 receptor agonist analog with two key structural modifications from native GLP-1: a substitution at position 8 that protects against DPP-4 enzymatic degradation, and a C-18 fatty diacid chain attached via a linker that enables reversible albumin binding. These modifications extend its half-life significantly compared to native GLP-1 in research models.

• GLP-1 receptor activation — stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, and slows gastric emptying in research models
• cAMP-mediated signaling — GLP-1R activation increases intracellular cAMP, activating PKA and EPAC pathways that regulate insulin gene expression and beta cell survival in preclinical studies
• Central nervous system effects — GLP-1 receptors are expressed in hypothalamic regions involved in appetite regulation; receptor activation in these areas is studied in energy homeostasis research
• Albumin binding via C-18 chain — the fatty acid modification enables non-covalent albumin binding, protecting the peptide from renal clearance and extending its research utility in pharmacokinetic studies

As a single GLP-1 receptor agonist, semaglutide is the standard reference compound for GLP-1R biology research, enabling direct comparison with dual agonists (tirzepatide) and triple agonists (retatrutide) to isolate GLP-1 receptor-specific effects.

---

Research Applications

Semaglutide is studied across several active research domains:

• GLP-1 receptor binding kinetics, agonist potency, and receptor desensitization studies
• cAMP signaling cascade and downstream PKA/EPAC pathway investigation
• Comparative incretin pharmacology — isolating GLP-1R effects vs dual and triple agonists
• Pancreatic beta cell function, insulin secretion, and glucose-stimulated insulin response
• Hypothalamic appetite regulation and energy expenditure modeling
• Fatty acid modification and albumin binding pharmacokinetic research
• GLP-1R expression profiling across tissue types in preclinical models
• Incretin effect studies comparing native GLP-1 vs structural analogs

---

Why Research Laboratories Select GLP1-S

Semaglutide is among the most studied GLP-1 receptor agonist analogs in current metabolic and endocrine research. Its structural modifications — including two amino acid substitutions compared to native GLP-1 and a C-18 fatty acid chain — give it enhanced stability and albumin binding properties, making it a valuable reference compound for laboratories studying sustained GLP-1 receptor activation, incretin signaling dynamics, and comparative receptor biology.

• 31 amino acid GLP-1 analog with C-18 fatty acid chain for enhanced stability in experimental settings
• Single receptor target — GLP-1R — useful for comparative studies against dual and triple agonists
• Extensively referenced in peer-reviewed literature on incretin biology and metabolic signaling
• Widely used as a reference compound in studies comparing GLP-1 class analogs
• Lyophilized format ensures stability and reproducibility across experimental runs
• Batch and lot identifiers on all labeling for full laboratory documentation compliance

---

Semaglutide vs. Tirzepatide vs. Retatrutide: Research Comparison

Compound	Receptor Targets	Agonist Type	Structural Feature
Semaglutide (GLP1-S)	GLP-1R	Single agonist	C-18 fatty diacid, albumin binding
Tirzepatide	GLP-1R, GIPR	Dual agonist	C-20 fatty diacid, albumin binding
Retatrutide	GLP-1R, GIPR, GCGR	Triple agonist	C-18 fatty diacid, albumin binding

This comparison table is provided for research reference only. All compounds listed are supplied for laboratory research use only and are not intended for human use.

---

Research Background

Semaglutide was first described in scientific literature in 2015 by Lau et al. in the Journal of Medicinal Chemistry. As a GLP-1 receptor agonist analog, it has been studied extensively in preclinical models examining GLP-1 receptor binding dynamics, cAMP-mediated signaling cascades, and comparative incretin pathway biology. Phase 3 clinical trials (SUSTAIN series) have been completed and published in peer-reviewed journals. All information provided here is for educational and reference purposes only and does not constitute medical or clinical guidance.

Reference sources: PubChem — Semaglutide | NEJM — SUSTAIN-6 Trial

---

Shipping & Fulfillment

• Ships from U.S. warehouses — Florida, North Carolina, and California
• Overnight and 2-day shipping available at checkout
• Same-day processing on orders placed before cutoff
• Discreet packaging with full tracking provided
• Bulk research orders welcome — contact us for volume pricing

---

Storage & Handling

• Store lyophilized peptide at -20°C away from light and moisture
• After reconstitution, store at 2–8°C and use promptly
• Avoid repeated freeze-thaw cycles to maintain integrity
• Handle using appropriate laboratory safety protocols
• Keep containers sealed when not in use

---

Frequently Asked Questions

---

For Research Use Only — Not for human or veterinary consumption • Not evaluated by the FDA • Supplied by Nextday Peptides for laboratory research applications only